MX9603091A - Intermediarios de cloropirimidina. - Google Patents

Intermediarios de cloropirimidina.

Info

Publication number
MX9603091A
MX9603091A MX9603091A MX9603091A MX9603091A MX 9603091 A MX9603091 A MX 9603091A MX 9603091 A MX9603091 A MX 9603091A MX 9603091 A MX9603091 A MX 9603091A MX 9603091 A MX9603091 A MX 9603091A
Authority
MX
Mexico
Prior art keywords
intermediates
chloropyrimide
processes
aminopurines
salts
Prior art date
Application number
MX9603091A
Other languages
English (en)
Other versions
MXPA96003091A (es
Inventor
Susan Mary Daluge
Michael Tolar Martin
Michelle Joanne Ferry
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10749873&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9603091(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of MXPA96003091A publication Critical patent/MXPA96003091A/es
Publication of MX9603091A publication Critical patent/MX9603091A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catalysts (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Liquid Crystal Substances (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se relaciona a ciertos intermediarios de pirimidina novedosos y sus dales, a procesos para su preparacion, y a procesos para su conversion a 2-aminopurinas substituidas en la posicion 9, las cuales son utiles en terapia médica.
MX9603091A 1994-02-04 1996-07-30 Intermediarios de cloropirimidina. MX9603091A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9402161A GB9402161D0 (en) 1994-02-04 1994-02-04 Chloropyrimidine intermediates
GB9402161.5 1994-02-04

Publications (2)

Publication Number Publication Date
MXPA96003091A MXPA96003091A (es) 1998-01-01
MX9603091A true MX9603091A (es) 1998-01-31

Family

ID=10749873

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9603091A MX9603091A (es) 1994-02-04 1996-07-30 Intermediarios de cloropirimidina.

Country Status (28)

Country Link
US (8) US6448403B1 (es)
EP (1) EP0741710B1 (es)
JP (1) JP3670012B2 (es)
KR (1) KR100355983B1 (es)
CN (2) CN1161343C (es)
AT (1) ATE192742T1 (es)
AU (1) AU690203B2 (es)
BR (1) BR9506667A (es)
DE (1) DE69516847T2 (es)
DK (1) DK0741710T3 (es)
ES (1) ES2148486T3 (es)
FI (1) FI112477B (es)
GB (1) GB9402161D0 (es)
GR (1) GR3033850T3 (es)
HK (1) HK1004087A1 (es)
HU (1) HU223096B1 (es)
IL (1) IL112539A (es)
MX (1) MX9603091A (es)
MY (1) MY113775A (es)
NO (1) NO310819B1 (es)
NZ (1) NZ278948A (es)
PL (1) PL183885B1 (es)
PT (1) PT741710E (es)
RU (1) RU2140913C1 (es)
SG (1) SG47918A1 (es)
TW (1) TW390877B (es)
WO (1) WO1995021161A1 (es)
ZA (1) ZA95884B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
CA2145928C (en) * 1994-04-27 2007-10-09 Gerhard Stucky N-(2-amino-4,6-dichloropyrimidin-5-yl)formamide, and a process for its preparation
SK284810B6 (sk) 1997-05-13 2005-12-01 Lonza Ag Spôsob výroby (1S,4R)- alebo (1R,4S)-4-(2-amino-6-chlór-9-H- purín-9-yl)-2-cyklopentén-1-metanolu
GB9721780D0 (en) * 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
AU2702899A (en) * 1997-10-24 1999-05-17 Glaxo Group Limited Process for preparing a chiral nucleoside analogue
WO1999024431A1 (en) * 1997-11-12 1999-05-20 Glaxo Group Limited Process for preparing a chiral nucleoside analogue
SK284416B6 (sk) * 1997-11-27 2005-03-04 Lonza Ag Spôsob výroby derivátov aminoalkoholov
PT1013647E (pt) * 1998-12-21 2003-04-30 Lonza Ag Processo de preparacao de n-(amino-4,6-di-halogenopirimidina)-formamidas
EP1423080A4 (en) * 2001-03-01 2009-06-03 Conforma Therapeutics Corp PROCESS FOR TREATING PROLIFERATIVE GENETIC DISORDERS WITH HSP90 INHIBITORS
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
US7241890B2 (en) * 2001-10-30 2007-07-10 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
US6780635B2 (en) 2001-12-27 2004-08-24 Council Of Scientific And Industrial Research Process for the preparation of optically active azabicyclo heptanone derivatives
KR100573859B1 (ko) * 2002-07-15 2006-04-25 경동제약 주식회사 9-[4-아세톡시-3-(아세톡시메틸)부트-1-일]-2-아미노푸린의제조방법
US7560231B2 (en) * 2002-12-20 2009-07-14 Roche Molecular Systems, Inc. Mannitol and glucitol derivatives
TW200510415A (en) * 2003-04-30 2005-03-16 Teva Pharma Process for the preparation of famciclovir
WO2004103979A1 (ja) * 2003-05-26 2004-12-02 Sumitomo Chemical Company, Limited Ｎ－（２－アミノ－４，６－ジクロロピリミジン－５－イル）ホルムアミドの製造方法
KR100573860B1 (ko) * 2003-06-13 2006-04-25 경동제약 주식회사 2-아미노-9-(2-치환에틸)푸린을 이용한 9-[4-아세톡시-3-(아세톡시메틸)부트-1-일]-2-아미노푸린의 제조방법
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
KR100573861B1 (ko) * 2003-07-18 2006-04-25 경동제약 주식회사 2-아미노-9-(2-할로게노에틸)푸린 및 그 중간체로서의 2-아미노-6,8-디클로로-9-(2-히드록시에틸)푸린의 제조방법
GB0320738D0 (en) * 2003-09-04 2003-10-08 Glaxo Group Ltd Novel process
WO2005026167A1 (en) * 2003-09-04 2005-03-24 Teva Pharmaceutical Industries Ltd. Process for preparing famciclovir
WO2005028434A2 (en) * 2003-09-18 2005-03-31 Conforma Therapeutics Corporation Novel heterocyclic compounds as hsp90-inhibitors
DE102004002055A1 (de) * 2004-01-15 2005-08-11 Degussa Ag Verfahren zur Herstellung von 2-Amino-4,6-dichlor-5-formamidopyrimidin
KR100939274B1 (ko) * 2004-08-16 2010-01-29 쿠아크 파마수티칼스 인코퍼레이티드 알티피801 억제제의 치료적 용도
MX2007011903A (es) 2005-03-30 2007-12-05 Conforma Therapeutics Corp Alquinil pirrolopirimidinas y analogos relacionados como inhibidores de hsp90.
GB2426247A (en) 2005-05-20 2006-11-22 Arrow Int Ltd Methods of preparing purine derivatives such as famciclovir
US20070105874A1 (en) * 2005-09-23 2007-05-10 Conforma Therapeutics Corporation Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors
EP1857458A1 (en) * 2006-05-05 2007-11-21 SOLMAG S.p.A. Process for the preparation of abacavir
CN100465174C (zh) * 2006-06-13 2009-03-04 中国科学院上海有机化学研究所 制备光学纯阿巴卡韦的方法
WO2008072074A1 (en) * 2006-12-11 2008-06-19 Aurobindo Pharma Limited An improved process for the preparation of purine derivative
EP1939196A1 (en) * 2006-12-21 2008-07-02 Esteve Quimica, S.A. Process for the preparation of abacavir
WO2008155613A1 (en) * 2007-06-21 2008-12-24 Aurobindo Pharma Ltd An improved process for preparing purine derivative
EP2085397A1 (en) 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
PT2531027E (pt) 2010-01-27 2015-09-16 Viiv Healthcare Co Combinação terapêutica compreendendo dolutegravir, abacavir e lamivudina
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
WO2014133085A1 (ja) 2013-02-27 2014-09-04 国立大学法人京都大学 がんの予防または治療用医薬組成物
CN104672239A (zh) * 2013-11-26 2015-06-03 上海迪赛诺化学制药有限公司 一种采用一锅法制备阿巴卡韦式v中间体的工艺
CN109456329B (zh) * 2018-11-19 2021-03-09 迪嘉药业集团有限公司 一种泛昔洛韦的制备方法
CN113292507B (zh) * 2021-06-25 2022-07-19 潍坊奥通药业有限公司 一种2-氨基-6-氯鸟嘌呤及其中间体的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485225D1 (de) 1983-08-18 1991-12-05 Beecham Group Plc Antivirale guanin-derivate.
EP0182024B1 (en) 1984-09-20 1991-04-03 Beecham Group Plc Purine derivatives and their pharmaceutical use
US4965270A (en) 1987-05-30 1990-10-23 Beecham Group P.L.C. Purine derivatives
GB8724765D0 (en) 1987-10-22 1987-11-25 Beecham Group Plc Process
US5631370A (en) 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
US4916224A (en) 1988-01-20 1990-04-10 Regents Of The University Of Minnesota Dideoxycarbocyclic nucleosides
GB2243609B (en) * 1988-01-20 1992-03-11 Univ Minnesota Dideoxydidehydrocarbocyclic pyrimidines
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB8916698D0 (en) 1989-07-21 1989-09-06 Beecham Group Plc Novel process
GB8918827D0 (en) 1989-08-17 1989-09-27 Beecham Group Plc Novel compounds
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
SK279618B6 (sk) 1992-01-22 1999-01-11 Lonza A.G. (Dir.:Basel) N-5-chránené 2,5-diamino-4,6-dichlórpyrimidíny a s
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
CA2145928C (en) 1994-04-27 2007-10-09 Gerhard Stucky N-(2-amino-4,6-dichloropyrimidin-5-yl)formamide, and a process for its preparation

Also Published As

Publication number Publication date
WO1995021161A1 (en) 1995-08-10
MY113775A (en) 2002-05-31
IL112539A0 (en) 1995-05-26
ATE192742T1 (de) 2000-05-15
GB9402161D0 (en) 1994-03-30
US20030187263A1 (en) 2003-10-02
NO963239L (no) 1996-10-02
JP3670012B2 (ja) 2005-07-13
IL112539A (en) 2000-08-31
CN1139924A (zh) 1997-01-08
ZA95884B (en) 1996-08-05
DE69516847T2 (de) 2000-10-26
DK0741710T3 (da) 2000-08-14
NO963239D0 (no) 1996-08-02
CN1105109C (zh) 2003-04-09
US6552193B1 (en) 2003-04-22
CN1388123A (zh) 2003-01-01
CN1161343C (zh) 2004-08-11
BR9506667A (pt) 1997-09-16
FI963070A0 (fi) 1996-08-02
FI963070A (fi) 1996-08-02
HK1004087A1 (en) 1998-11-13
PL183885B1 (pl) 2002-07-31
PT741710E (pt) 2000-09-29
KR100355983B1 (ko) 2002-12-28
PL315713A1 (en) 1996-11-25
HUT75300A (en) 1997-05-28
JPH09508412A (ja) 1997-08-26
ES2148486T3 (es) 2000-10-16
TW390877B (en) 2000-05-21
HU223096B1 (hu) 2004-03-29
US6870053B2 (en) 2005-03-22
EP0741710A1 (en) 1996-11-13
US6448403B1 (en) 2002-09-10
US6555687B1 (en) 2003-04-29
FI112477B (fi) 2003-12-15
NO310819B1 (no) 2001-09-03
US20020173649A1 (en) 2002-11-21
SG47918A1 (en) 1998-04-17
NZ278948A (en) 1998-01-26
AU1543895A (en) 1995-08-21
US6087501A (en) 2000-07-11
DE69516847D1 (de) 2000-06-15
US5917042A (en) 1999-06-29
US5917041A (en) 1999-06-29
RU2140913C1 (ru) 1999-11-10
GR3033850T3 (en) 2000-10-31
HU9602114D0 (en) 1996-09-30
AU690203B2 (en) 1998-04-23
EP0741710B1 (en) 2000-05-10

Similar Documents

Publication Publication Date Title
HU9602114D0 (en) Chloropyrimide intermediates
ZA9710098B (en) Halogenopyrimidines.
MX9700885A (es) Nuevas heteroariloxazolidinonas.
DE69905170D1 (en) Thiazolopyrimidinderivate
BG101110A (en) Substituted pyrimidine compounds and their application
AU9744298A (en) Substituted tetrahydronaphthaline and analogous compounds
IL114294A0 (en) Sterol derivatives
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
GB9425730D0 (en) Compounds
MY113092A (en) Cisapride extended release
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
PL346015A1 (en) Methoximinophenylacetic acid amides
MX9700113A (es) Amido-quinoxalindionas novedosas, su preparacion y uso.
AU6722498A (en) Disubstituted biphenyloxazolines
DE50006244D1 (en) Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine
IL124354A0 (en) Hemoregulatory compounds
MX9804068A (es) Nuevos derivados de quinoxalindiona, su preparacion y empleo en medicamentos.
CA2182105A1 (en) Chloropyrimide intermediates
TW282449B (es)
AU2358301A (en) Glyoxyl acid amides
MX9700421A (es) Tienil- y furanil- oxazolidinonas piridocondensadas.